WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H532366
CAS#: 204326-43-2
Description: NS 2028 is a potent soluble guanylyl cyclase (sGC) inhibitor (Ki = 8 nM). It blocks sGC activity in murine cerebellum induced by S-nitroso-glutathione and NMDA (IC50 values are 17 and 20 nM respectively). NS 2028 also inhibits VEGF-induced cGMP accumulation.
Hodoodo Cat#: H532366
Name: NS 2028
CAS#: 204326-43-2
Chemical Formula: C9H5BrN2O3
Exact Mass: 267.95
Molecular Weight: 269.054
Elemental Analysis: C, 40.18; H, 1.87; Br, 29.70; N, 10.41; O, 17.84
Synonym: NS 2028; NS-2028; NS2028.
IUPAC/Chemical Name: 8-bromo-4H-[1,2,4]oxadiazolo[3,4-c][1,4]benzoxazin-1-one
InChi Key: MUDRLQRJCGJJTB-UHFFFAOYSA-N
InChi Code: InChI=1S/C9H5BrN2O3/c10-5-1-2-7-6(3-5)12-8(4-14-7)11-15-9(12)13/h1-3H,4H2
SMILES Code: O=C1ON=C2COC3=CC=C(Br)C=C3N21
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 269.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Fang F, Pan M, Yan T, Tao Y, Wu H, Liu X, Qu J, Zhou X. The role of cGMP in ocular growth and the development of form-deprivation myopia in guinea pigs. Invest Ophthalmol Vis Sci. 2013 Dec 3;54(13):7887-902. doi: 10.1167/iovs.13-11999. PubMed PMID: 24130184.
2: Sawa T, Ihara H, Ida T, Fujii S, Nishida M, Akaike T. Formation, signaling functions, and metabolisms of nitrated cyclic nucleotide. Nitric Oxide. 2013 Nov 1;34:10-8. doi: 10.1016/j.niox.2013.04.004. Epub 2013 Apr 28. Review. PubMed PMID: 23632125.
3: Schallner N, Romão CC, Biermann J, Lagrèze WA, Otterbein LE, Buerkle H, Loop T, Goebel U. Carbon monoxide abrogates ischemic insult to neuronal cells via the soluble guanylate cyclase-cGMP pathway. PLoS One. 2013 Apr 8;8(4):e60672. doi: 10.1371/journal.pone.0060672. Print 2013. PubMed PMID: 23593279; PubMed Central PMCID: PMC3620383.